Immunotherapy in Lung Cancer

The benefits of immunotherapy in patients with the target when you take it became a major topic. We now know that targeted therapies and immunotherapies don't really mix well in lung cancer populations. Of course, there are exceptions, but it also looks like the population to derive benefit. If we think of the Venn diagram, there are the oncogenic drivers that really don't drive benefit to immunotherapy. So I would put BRAF in that category as well.